Salestools LogoSalestools
Salestools LogoSalestools
Biotech

Freenome

Freenome raises $290M Series D at $1.1B valuation

$290M
Total Raised
Series D
Latest Round
2014
Founded
400+
Employees
279 East Grand Avenue, South San Francisco, CA 94080
1 min read

Quick Facts

Valuation
$1.1B
Latest Round Size
$290M
Latest Round Date
January 2024

Freenome: Series D Funding Round

Freenome has successfully raised $290M in Series D funding, reaching a valuation of $1.1B.

Company Overview

AI-driven early cancer detection

Funding Details

The Series D round was led by Perceptive Advisors, with participation from RA Capital Management, Andreessen Horowitz, GV, T. Rowe Price, Roche Venture Fund.

Company Information

  • Headquarters: 279 East Grand Avenue, South San Francisco, CA 94080
  • Founded: 2014
  • Employees: 400+
  • Category: Biotech

Investment

Freenome plans to use the funds to accelerate product development, expand its team, and scale operations globally.

About the Investors

  • Perceptive Advisors: Verified investor in Series D
  • RA Capital Management: Verified investor in Series D
  • Andreessen Horowitz: Verified investor in Series D
  • GV: Verified investor in Series D
  • T. Rowe Price: Verified investor in Series D
  • Roche Venture Fund: Verified investor in Series D

Key Investors

Perceptive Advisors
Lead Investor
Verified investor in Series D
RA Capital Management
Investor
Verified investor in Series D
Andreessen Horowitz
Investor
Verified investor in Series D
GV
Investor
Verified investor in Series D
T. Rowe Price
Investor
Verified investor in Series D
Roche Venture Fund
Investor
Verified investor in Series D

Topics

verified(3079)real-funding(3079)freenomebiotechseries-d279-east-grand-avenue

About the Author

Editorial Team
Editorial Team
Curated funding news from verified sources

Related Company Reports

Biotech
Orna Therapeutics

Orna Therapeutics Raises $251M Series B

Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases

Emma Rodriguez
Emma Rodriguez
Oct 23, 2025
0 min read•$251M Series B
Biotech
Forge Biologics

Forge Biologics Raises $120M Series C

Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines

Sarah Kim
Sarah Kim
Oct 23, 2025
0 min read•$120M Series C
Biotech
Vir Biotechnology

Vir Biotechnology Raises $250M

Clinical-stage immunology company developing treatments for infectious diseases including COVID-19, hepatitis B, and influenza

Sarah Kim
Sarah Kim
Oct 23, 2025
0 min read•$250M